Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.57
-5.30 (-3.76%)
Streaming Delayed Price
Updated: 1:24 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
54
55
Next >
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
October 23, 2023
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at...
Via
Talk Markets
Topics
Economy
Exposures
Economy
3 Stocks to Buy From the ‘Buy the Dip’ ETF
October 23, 2023
It’s a lot harder than it looks to buy the dip. Using artificial intelligence to do this makes these three stocks a buy.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Healthcare Stocks to Invest in for a Big Shot of Gains
October 23, 2023
While healthcare stocks are down for the most part this year, there are a few names that offer the promise of big future profits.
Via
InvestorPlace
2 Stock-Split Stocks That Could Plunge Up to 89%, According to Select Wall Street Analysts
October 23, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are two high-flying stock-split stocks a pair of analysts believe will lose their...
Via
The Motley Fool
$1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today
October 20, 2023
Via
Benzinga
Novo Nordisk Unusual Options Activity
October 19, 2023
Via
Benzinga
3 Unstoppable Stocks to Buy Sooner Rather Than Later
October 22, 2023
Now is the time to invest in these great stocks.
Via
The Motley Fool
Is Your Weight-loss Medication Genuine? Demand For Drugs From Novo Nordisk And Eli Lilly Leads To Surge In Counterfeits
October 21, 2023
As obesity rates climb worldwide, so does the demand
Via
Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
This Stock-Split Stock Is Beating Both Apple and Microsoft in 2023 -- With No Artificial Intelligence (AI) Tailwind at All
October 21, 2023
This big pharma stock has been a big winner, thanks to two blockbuster drugs.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Mutual Funds to Invest in for Pro Management and Low Fees
October 20, 2023
People wanting to invest for the future without actively managing their own money should consider one of these top mutual funds.
Via
InvestorPlace
Two Stocks Set to Capitalize on the Surging Weight Loss Drug Trend
October 19, 2023
Several drugmakers have been thriving on the ongoing weight-loss trend, with Denmark's Novo Nordisk and Eli Lilly standing out in particular.
Via
Talk Markets
1 Market-Beating Stock to Buy Near Its 52-Week High
October 19, 2023
This stock has been firing on all cylinders -- and it isn't about to stop.
Via
The Motley Fool
4 Ways to Grow $100,000 Into $1 Million for Retirement
October 19, 2023
Investing for big-time growth doesn't have to be risky.
Via
The Motley Fool
1 Thing You'd Better Know Before You Invest in the Stocks Behind Ozempic and Mounjaro
October 19, 2023
Eli Lilly and Novo Nordisk are both battling demand issues for flagship treatments.
Via
The Motley Fool
Beware Of Fake Novo Nordisk's Ozempic - European, UK Regulators Warn About Fake Prefilled Pens
October 19, 2023
The European Medicines Agency warned about pre-filled pens falsely labeled as Novo Nordisk A/S's (NYSE: NVO) popular diabetes drug Ozempic at wholesalers in the
Via
Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
7 Stocks to Buy and Hold for a Lifetime of Wealth
October 19, 2023
The best way to live a stress-free life and build wealth in the long term is to choose stocks to buy and hold. Here are 7 that fit the bill.
Via
InvestorPlace
How Consumer Goods Will Survive the Negative Impacts of Ozempic
October 18, 2023
Ozempic is a popular drug doctors are prescribing to millions of patients to fight obesity and diabetes. CNBC reports that in the first six months of 2023 alone, Ozempic sales have grown by 58%.
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Is the Ozempic-Driven DexCom Selloff Overdone?
October 18, 2023
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly?
Via
MarketBeat
3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits
October 18, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three stock-split stocks select people on Wall Street believe offer...
Via
The Motley Fool
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
October 17, 2023
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via
Chartmill
Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.
October 17, 2023
What's good for Novo Nordisk's Ozempic is also good for Eli Lilly's Mounjaro.
Via
The Motley Fool
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
October 16, 2023
Investors should brush off Ozempic selloff fears and dive into tasty food and beverage stocks that have been oversold in 2023.
Via
InvestorPlace
Snack Maker Mondelez Int'l Is Down but Not Out
October 16, 2023
If Mondelez beats consensus for Q3 and can offer reassurance about the potential impact of Ozempic, investors’ appetite for chewed up snack makers may improve.
Via
MarketBeat
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.
Via
Benzinga
Barron's Weekend Stock Picks: Truist Financial, Groupon And Nvidia's Rising Stock
October 15, 2023
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.
Via
Benzinga
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
October 14, 2023
Can concerns about side effects derail the growth of these incredibly popular drugs?
Via
The Motley Fool
Johnson & Johnson Stock: Is Now the Time to Sell?
October 14, 2023
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff
Via
InvestorPlace
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.